By Eric Schweibenz
On April 2, 2015, Chief ALJ Charles E. Bullock issued Order No. 51 in Certain Hemostatic Products and Components Thereof (Inv. No. 337-TA-913).

By way of background, this investigation is based on a complaint filed by Baxter International Inc., Baxter Healthcare Corp., and Baxter Healthcare S.A. (collectively, "Baxter") alleging violation of Section 337 by Ethicon, Inc. and Ferrosan Medical Devices A/S (collectively, the "Respondents") in the importation into the U.S. and sale of certain hemostatic products that infringe one or more claims of U.S. Patent Nos. 8,303,981; 8,512,729; 6,066,325; 8,357,378; and 8,603,511 (collectively, the "Asserted Patents").  See our March 5, 2014 and April 4, 2014 posts for more details on the complaint and Notice of Investigation, respectively.

According to the Order, ALJ Bullock granted Baxter's motion to terminate the investigation as to Respondents based on a settlement agreement between Baxter and the Respondents.